Conclusion and Implications
In conclusion, pirfenidone and nintedanib, either administered
individually or in combination, exhibit remarkable potential in advanced
silicosis mouse models. Further, combined therapy outperformed
monotherapy even at a half dose. These therapeutic benefits are
attributed to their influence on diverse signaling pathways and
metabolic processes.
Keywords: silicosis, pulmonary fibrosis, pirfenidone,
nintedanib, multi-omics.